StockData

Autonomix Medical vs Orchestra BioMed

AMIX and OBIO side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMIX and OBIO compare

Orchestra BioMed is the larger company, worth 328 times as much as Autonomix Medical ($436M against $1.3M).

Orchestra BioMed scores higher on the StockData Score (9 against 6 for Autonomix Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMIXOBIO
Size and price
Market cap$1.3M$436M
Share price$1.37$7.25
Change, 1 year−92.3%64.0%
Change, 5 years–−26.5%
Beta (5Y)1.560.84
Employees1186
StockData Score
Total score69 (better)
Valuation score1 (better)0
Growth score03 (better)
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/S–14.0×
P/B0.2×–
FCF yield–−14.7%
Growth
Revenue growth (TTM)–1007%
Profitability
Gross margin–99.6%
Operating margin–−195%
Net margin–−183%
FCF margin–−206%
Return on equity−176%–
Financial health
Debt / equity0.00–
Current ratio6.527.25 (better)
Altman Z-score−15.66−3.18 (better)
Piotroski F-score26 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions5.2%46.1%
Held by insiders7.8%56.6%
Insider net buying, 12 months–$6.1M
Short interest, % of float6.2%10.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.